AdvaCare is a GMP manufacturer of Cefpirome Sulphate powder for injections.
Cefpirome Sulphate Powder for Injection is a semisynthetic fourth generation cephalosporin intended for intravenous administration.
Cefpirome is highly active against a wide range of gram-positive and gram-negative organisms.
Cefpirome sulphate is indicated for lower respiratory tract infections (bronchopneumonia, lobar pneumonia); complicated upper (pyelonephritis) and lower urinary tract infections; skin and soft tissue infections (cellulitis wound infections); bacteremia/ septicemia and severe infections in intensive care patients; infections in neutropenic and immunocompromised patients.
As with all pharmaceuticals, some unwanted effects can occur from the use of cefpirome sulphate. Always consult a doctor or health care professional for medical advice before use.
Common side effects include Thrombocytopenia, Hemolytic anemia, Hemolytic anemia, Granulocytopenia, Eosinophilia, Agranulocytosis, Elevated hepatic enzymes, Superinfection.
Cefpirome produces potentially life-threatening effects which include Anaphylaxis which are responsible for the discontinuation of Cefpirome therapy.
The symptomatic adverse reactions produced by Cefpirome are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Abdominal pain, Rashes, Urticaria, Pseudomembranous colitis, Increase in liver enzymes.
For a comprehensive list of all possible effects, consult your doctor.
If any symptom persists or gets worse, or you notice any other symptom, then please call your doctor immediately.